Global Cell and Gene Therapy Drug Delivery Devices Market: Focus on Product Type, Commercialized Drug Delivery Devices, Country Data (16 Countries), and Competitive Landscape – Analysis and Forecast, 2020-2030

Table of Contents

Executive Summary 1 Technology Definition 1.1 Inclusion and Exclusion Criteria 1.1.1 Inclusions 1.1.2 Exclusions 2 Research Scope 3 Key Questions Answered in the Report 4 Research Methodology 4.1 Cell and Gene Therapy Drug Delivery Devices: Research Methodology 4.2 Primary Data Sources 4.3 Secondary Data Sources 4.4 Market Estimation Model 4.5 Criteria for Company Profiling 5 Market Overview 5.1 Introduction 5.2 Cell and Gene Therapies and Drug Delivery Devices Industry 5.3 Cell and Gene Therapy Drugs and Their Clinical Importance 5.4 Cell and Gene Therapy Drug Delivery Devices Market: Current Scenario 5.5 Cell and Gene Therapy Drug Delivery Devices Market: Future Perspective 6 Global Cell and Gene Therapy Drug Delivery Devices Market and Growth Potential, 2020-2030 6.1 Overview 6.2 Pipeline Analysis 6.2.1 Drug Delivery Systems in Development: Current Scenario 6.2.1.1 Ongoing Clinical Trials of Drug Delivery Systems 6.2.1.2 Limitations of Cell and Gene Therapy Drug Delivery Devices 6.2.1.3 Recent Advancements in Gene Therapy Drug Delivery 6.3 Cell and Gene Therapy Drug Delivery Devices Market and Growth Potential 6.4 Cell and Gene Therapy Drug Development and Commercialization Landscape 6.5 Impact of COVID-19 on Cell and Gene Therapy Drug Delivery Devices Market 6.5.1 Impact of COVID-19 on Global Cell and Gene Therapy Drug Delivery Devices Market Growth Rate 6.5.2 Impact of COVID-19 on Supply Chain of Cell and Gene Therapy Drug Delivery Devices Market 6.5.3 Clinical Trial Disruptions and Resumptions 7 Emerging Technology Landscape 7.1 Potential Technologies in Cell and Gene Therapy Drug Delivery Devices Market 7.2 Microchip Technology 7.3 Nanotechnology-Based Drug Delivery Devices 7.4 Lipid Nanoparticles in Gene Therapy 8 Market Dynamics 8.1 Impact Analysis 8.2 Market Drivers 8.2.1 Increasing Prevalence of Cancer and Chronic Diseases 8.2.2 Increased Funding of Cell and Gene Therapies 8.2.3 Rising Number of FDA Approvals of Cell and Gene Therapies, and Clinical Trials 8.3 Market Restraints 8.3.1 Stringent Legal Requirements and Regulations 8.3.2 Injuries and Infections Caused by Needles 8.4 Market Opportunities 8.4.1 Strong Pipeline of Cell and Gene Therapies 9 Industry Insights 9.1 Regulatory Scenario of Cell and Gene Therapy Drug Delivery Devices Market 9.1.1 Overview 9.1.2 Risk Assessment of Medical Devices 9.1.3 Regulation of Medical Devices in the U.S. 9.1.3.1 Food and Drug Administration (FDA) 9.1.3.2 Food and Drug Administration (FDA) Regulations Modification 9.1.4 Regulation of Medical Devices in Europe 9.1.4.1 Regulations in Europe – Highlights 9.1.4.2 EU Regulatory Pathway for Medical Device 9.1.4.3 Federal Agencies of EU Member States 9.1.4.4 European Commission Regulations Modification 9.1.5 Regulation of Medical Devices in Asia-Pacific 9.1.5.1 Overview 9.1.5.2 Regulatory and Market Access Challenges in Asia-Pacific 9.1.5.3 Regulatory Environment for Medical Devices in China 9.2 Pricing and Reimbursement of Cell and Gene Therapy Drug Delivery Devices 10 Patent Landscape 11 Global Cell and Gene Therapy Drug Delivery Devices Market (by Product Type) 11.1 Overview 11.2 Subretinal Injection Cannula 11.3 Extension Tube 11.4 Intravenous Catheter 11.5 Sterile Insulin Syringe 11.5.1 Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle) 11.5.2 Sterile Insulin Syringe (Size 0.5 ML, 22 Gauge Needle) 11.6 Pre-Filled Syringe 11.6.1 Pre-Filled Syringe (Size 1.0 ML, 22-26 Gauge Needle) 11.6.2 Pre-Filled Syringe (Size 4.0 ML, 22-26 Gauge Needle) 11.7 Infusion Bags 11.7.1 Infusion Bags (Size 10 ML to 50 ML) 11.7.2 Infusion Bags (Size 68 ML) 11.7.3 Infusion Bags (Size 60 ML) 11.7.4 Infusion Bags (Size Up to 65 ML) 12 Global Cell and Gene Therapy Drug Delivery Devices Market (by Commercialized Drugs) 12.1 Commercialized Drugs 12.1.1 Luxturna 12.1.2 Kymriah 12.1.3 Provenge 12.1.4 Zolgensma 12.1.5 Yescarta 12.1.6 Strimvelis 13 Global Cell and Gene Therapy Drug Delivery Devices Market (by Region) 13.1 Overview 13.2 North America 13.2.1 U.S. 13.2.1.1 Approved Products 13.2.1.2 Market Size and Forecast 13.2.1.3 Key Developments 13.2.2 Canada 13.2.2.1 Approved Products 13.2.2.2 Market Size and Forecast 13.2.2.3 Key Developments 13.3 Europe 13.3.1 Germany 13.3.1.1 Approved Products 13.3.1.2 Market Size and Forecast 13.3.1.3 Key Developments 13.3.2 France 13.3.2.1 Approved Products 13.3.2.2 Market Size and Forecast 13.3.2.3 Key Developments 13.3.3 U.K. 13.3.3.1 Approved Products 13.3.3.2 Market Size and Forecast 13.3.4 Italy 13.3.4.1 Approved Products 13.3.4.2 Market Size and Forecast 13.3.4.3 Key Developments 13.3.5 Spain 13.3.5.1 Approved Products 13.3.5.2 Market Size and Forecast 13.3.5.3 Key Developments 13.3.6 Netherlands 13.3.6.1 Approved Products 13.3.6.2 Market Size and Forecast 13.3.6.3 Key Developments 13.3.7 Russia 13.3.7.1 Approved Products 13.3.7.2 Market Size and Forecast 13.3.8 Rest-of-Europe 13.3.8.1 Market Size and Forecast 13.3.8.2 Key Developments 13.4 Asia-Pacific 13.4.1 Japan 13.4.1.1 Approved Products 13.4.1.2 Market Size and Forecast 13.4.1.3 Key Developments 13.4.2 China 13.4.2.1 Approved Products 13.4.2.2 Market Size and Forecast 13.4.2.3 Key Developments 13.4.3 Australia 13.4.3.1 Approved Products 13.4.3.2 Market Size and Forecast 13.4.3.3 Key Developments 13.4.4 South Korea 13.4.4.1 Approved Products 13.4.4.2 Market Size and Forecast 13.4.4.3 Key Developments 13.4.5 India 13.4.5.1 Approved Products 13.4.6 Singapore 13.4.6.1 Market Size and Forecast 13.4.6.2 Key Developments 13.4.7 Rest-of-Asia-Pacific 13.4.7.1 Market Size and Forecast 13.4.7.2 Key Developments 13.5 Latin America 13.5.1 Brazil 13.5.1.1 Market Size and Forecast 13.5.2 Mexico 13.5.2.1 Market Size and Forecast 13.5.3 Rest-of-Latin America 13.5.3.1 Market Size and Forecast 13.6 Rest-of-World 13.6.1 Market Size and Forecast 14 Competitive Landscape 14.1 Key Developments and Strategies 14.1.1 Overview 14.1.2 Regulatory and Legal Developments 14.1.3 Synergistic Activities 14.1.4 M&A Activities 14.1.5 Funding Activities 14.2 Market Share Analysis 15 Company Profiles 15.1 Overview 15.2 Amgen Inc. 15.2.1 Company Overview 15.2.2 Role of Amgen Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market 15.2.3 Financials 15.2.4 R&D Expenditure, 2017-2019 15.2.5 SWOT Analysis 15.3 Bausch & Lomb Incorporated. 15.3.1 Company Overview 15.3.2 Role of Bausch & Lomb Incorporated., in the Global Cell and Gene Therapy Drug Delivery Devices Market 15.3.3 Financials 15.3.4 Key Insights About Financial Health of the Company 15.3.5 SWOT Analysis 15.4 Becton, Dickinson and Company 15.4.1 Company Overview 15.4.2 Role of Becton, Dickinson and Company in the Global Cell and Gene Therapy Drug Delivery Devices Market 15.4.3 Financials 15.4.4 Key Insights About Financial Health of the Company 15.4.5 SWOT Analysis 15.5 Bluebird bio, Inc. 15.5.1 Company Overview 15.5.2 Role of Bluebird bio, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market 15.5.3 Financials 15.5.4 R&D Expenditure, 2017-2019 15.5.5 SWOT Analysis 15.6 Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.) 15.6.1 Company Overview 15.6.2 Role of Castle Creek Biosciences, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market 15.6.3 Key Insights About Financial Health of the Company 15.6.4 SWOT Analysis 15.7 Dendreon Pharmaceuticals LLC. 15.7.1 Company Overview 15.7.2 Role of Dendreon Pharmaceuticals LLC. in the Global Cell and Gene Therapy Drug Delivery Devices Market 15.7.3 SWOT Analysis 15.8 Helixmith Co., Ltd (ViroMed Co., Ltd) 15.8.1 Company Overview 15.8.2 Role of Helixmith Co., Ltd. in the Global Cell and Gene Therapy Drug Delivery Devices Market 15.8.3 Financials 15.8.4 SWOT Analysis 15.9 Human Stem Cells Institute 15.9.1 Company Overview 15.9.2 Role of Human Stem Cell Institute in Global Cell and Gene Therapy Drug Delivery Devices Market 15.9.3 SWOT Analysis 15.1 Kite Pharma, Inc. 15.10.1 Company Overview 15.10.2 Role of Kite Pharma, Inc in Global Cell and Gene Therapy Drug Delivery Devices Market 15.10.3 Financials 15.10.4 R&D Expenditure, 2017-2019 15.10.5 SWOT Analysis 15.11 Kolon TissueGene, Inc. 15.11.1 Company Overview 15.11.2 Role of Kolon TissueGene, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market 15.11.3 SWOT Analysis 15.12 Novartis AG 15.12.1 Company Overview 15.12.2 Role of Novartis AG in the Global Cell and Gene Therapy Drug Delivery Devices Market 15.12.3 Financials 15.12.4 R&D Expenditure, 2017-2019 15.12.5 SWOT Analysis 15.13 Orchard Therapeutics plc. 15.13.1 Company Overview 15.13.2 Role of Orchard Therapeutics plc. in the Global Cell and Gene Therapy Drug Delivery Devices Market 15.13.3 Financials 15.13.4 SWOT Analysis 15.14 Pfizer, Inc. 15.14.1 Company Overview 15.14.2 Role of Pfizer, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market 15.14.3 Financials 15.14.4 R&D Expenditure, 2017-2019 15.14.5 SWOT Analysis 15.15 Renova Therapeutics 15.15.1 Company Overview 15.15.2 Role of Renova Therapeutics in Global Cell and Gene Therapy Drug Delivery Devices Market 15.15.3 SWOT Analysis 15.16 Spark Therapeutics, Inc. 15.16.1 Company Overview 15.16.2 Role of Spark Therapeutics, Inc. in Global Cell and Gene Therapy Drug Delivery Devices Market 15.16.3 Financials 15.16.4 Key Insights About Financial Health of the Company 15.16.5 SWOT Analysis 15.17 uniQure N.V. 15.17.1 Company Overview 15.17.2 Role of uniQure N.V. in Global Cell and Gene Therapy Drug Delivery Devices Market 15.17.3 SWOT Analysis 15.18 Vericel Corporation 15.18.1 Company Overview 15.18.2 Role of Vericel Corporation in the Global Cell and Gene Therapy Drug Delivery Devices Market 15.18.3 Financials 15.18.4 Key Insights About Financial Health of the Company 15.18.5 SWOT Analysis List of Tables Table 1: Evolution of Controlled Drug Delivery Systems: 30 Years (2000-2030) Table 5.1: Drug Delivery Methods of Cell and Gene Therapeutics Table 5.2: Commercialized Drugs of Cell and Gene Therapy Drug Delivery Devices Market, Device Size and Specification Table 5.3: Comparison of Major Routes of Drug Delivery for Systemic Absorption Table 6.1: Ongoing Clinical Trials of Drug Delivery Systems Table 6.2: Commercialized Drugs of Cell and Gene Therapy Drug Delivery Devices Market Table 7.1: Pipeline Drug Delivery Devices for Cell and Gene Therapy Table 7.2: Drug Delivery Based on Lab-on-a-Chip Technology Table 7.3: Nanomaterials and Nanobiotechnologies used for Drug Delivery Table 7.4: Globally Approved Lipid Nanoparticles Therapies Table 8.1: Commercialized Cell and Gene Therapies in the Market Table 8.2: Filing Requirements for Pre-Filled Syringes Table 8.3: Differentiation of an Injectable Therapeutic Throughout its Life Cycle Table 9.1: European Commission Medical Device Directives Table 9.2: Federal Agencies of EU Member States Table 9.3: Key Market Access Landscape (9 Countries), January 2019 Table 9.4: Average Selling Price of Cell and Gene Therapy Drug Delivery Devices, (2019 and 2030) Table 10.1: Patents for Cell and Gene Therapy Drug Delivery Devices Table 13.1: List of Cell and Gene Therapy Products with Marketing Authorization in the European Union by EMA List of Figures Figure 1: Global Geriatric Population by Age Figure 2: Global Cell and Gene Therapy Drug Delivery Devices Market Snapshot Figure 3: Dominant Segments of the Global Cell and Gene Therapy Drug Delivery Devices Market, 2019 and 2030 Figure 4: Global Cell and Gene Therapy Drug Delivery Devices Market (by Product Type), 2019 and 2030 Figure 5: Global Cell and Gene Therapy Drug Delivery Devices Market (by Region), 2019 and 2030 Figure 6: Global Cell and Gene Therapy Drug Delivery Devices: Impact Analysis Figure 7: Leading Players in Global Cell and Gene Therapy Drug Delivery Devices Market Figure 2.1: Global Cell and Gene Therapy Drug Delivery Devices Market Segmentation Figure 4.1: Global Cell and Gene Therapy Drug Delivery Devices Market Methodology Figure 4.2: Primary Research Methodology Figure 4.3: Bottom-Up Approach (Segment-Wise Analysis) Figure 4.4: Top-Down Approach (Segment-Wise Analysis) Figure 5.1: Clinical Trials by Therapeutic Category, Cell and Gene Therapy, 2018 Figure 6.1: Global Cell and Gene Therapy Drug Delivery Devices Market, $Thousand, 2019 and 2030 Figure 6.2: Cell and Gene Therapy Clinical Trials (by Phase) Figure 6.3: Global Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 6.4: Cell and Gene Therapy Drug Delivery Devices Market (by Commercialized Products) 2019 Figure 6.5: Cell and Gene Therapy Drug Delivery Devices Market (by Commercialized Products), 2030 Figure 6.6: Most Impacted Practices in Cell and Gene Therapy Drug Delivery Devices Market Figure 6.7: Impact of COVID-19 on Cell and Gene Therapy Drug Delivery Devices Market Figure 6.8: Major Areas of Disruption Figure 6.9: Impact of COVID-19 on Clinical Trials Figure 6.10: Status of Clinical Trials (April 2020–July 2020) Figure 6.11: Disrupted Clinical Trials (by Phase of Clinical Trial) Figure 6.12: Disrupted Clinical Trials (by Therapy Area) Figure 7.1: Interrelationship of Drug Delivery Devices, Pharmaceutical Industry, and Biotechnology Figure 8.1: Global Cell and Gene Therapy Drug Delivery Devices: Impact Analysis Figure 8.2: Total Burden of Diseases (by Cause), 2017 Figure 8.3: Number of Active and Completed Clinical Trials for Cell and Gene Therapy, 2014-2018 Figure 8.4: Total Percutaneous Injuries Reported by Drug Delivery Device Figure 9.1: Risk Assessment of Medical Devices Figure 9.2: FDA Regulatory Pathway for Medical Device Figure 9.3: FDA Regulations Modification: Pre-COVID-19 Phase to Post-COVID-19 Phase Figure 9.4: EU Regulatory Pathway for Medical Device Figure 9.5: European Commission Regulations Modification: Pre-COVID-19 Phase to Post-COVID-19 Phase Figure 9.6: Regulatory and Market Access Challenges in Asia-Pacific Figure 9.7: Regulatory Environment for Medical Devices in China Figure 9.8: Chinese Medical Device Classification and Pre-Market Requirement Figure 10.1: Share of Patents (by Ownership), 2016-2019 Figure 11.1: Revenue Contribution of Different Segments, 2020 and 2030 Figure 11.2: Subretinal Injection Cannula (by Volume), 2019-2030 Figure 11.3: Subretinal Injection Cannula (by Value), 2019-2030 Figure 11.4: Extension Tube (by Volume), 2019-2030 Figure 11.5: Extension Tube (by Value), 2019-2030 Figure 11.6: Intravenous Catheter (by Volume), 2019-2030 Figure 11.7: Intravenous Catheter (by Value), 2019-2030 Figure 11.8: Revenue Contribution of Sterile Insulin Syringe Segments, 2019 and 2030 Figure 11.9: Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle) (by Volume), 2019-2030 Figure 11.10: Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle) (by Value), 2019-2030 Figure 11.11: Sterile Insulin Syringe (Size 0.5 ML, 22 Gauge Needle) (by Volume), 2019-2030 Figure 11.12: Sterile Insulin Syringe (Size 0.5 ML, 22 Gauge Needle) (by Value), 2019-2030 Figure 11.13: Revenue Contribution of Pre-Filled Syringe Segments, 2019 and 2030 Figure 11.14: Pre-Filled Syringe (Size 1.0 ML, 22-26 Gauge Needle) (by Volume), 2019-2030 Figure 11.15: Pre-Filled Syringe (Size 1.0 ML, 22-26 Gauge Needle) (by Value), 2019-2030 Figure 11.16: Pre-Filled Syringe (Size 4.0 ML, 22-26 Gauge Needle) (by Volume), 2019-2030 Figure 11.17: Pre-Filled Syringe (Size 4.0 ML, 22-26 Gauge Needle) (by Value), 2019-2030 Figure 11.18: Revenue Contribution of Infusion Bag Segments, 2019 and 2030 Figure 11.19: Infusion Bag (Size 10 ML to 50 ML) (by Volume), 2019-2030 Figure 11.20: Infusion Bag (Size 10 ML to 50 ML) (by Value), 2019-2030 Figure 11.21: Infusion Bag (68 ML) (by Volume), 2019-2030 Figure 11.22: Infusion Bag (68 ML) (by Value), 2019-2030 Figure 11.23: Infusion Bag (60 ML) (by Volume), 2019-2030 Figure 11.24: Infusion Bag (60 ML) (by Value), 2019-2030 Figure 11.25: Infusion Bag (Size Up to 65 ML) (by Volume), 2019-2030 Figure 11.26: Infusion Bag (Size Up to 65 ML) (by Value), 2019-2030 Figure 12.1: Luxturna Drug Delivery Devices (by Volume), 2019 and 2030 Figure 12.2: Luxturna Drug Delivery Devices (by Value), 2019 and 2030 Figure 12.3: Kymriah Drug Delivery Devices (by Volume), 2019 and 2030 Figure 12.4: Kymriah Drug Delivery Devices (by Value), 2019 and 2030 Figure 12.5: Provenge Drug Delivery Devices (by Volume), 2019 and 2030 Figure 12.6: Provenge Drug Delivery Devices (by Value), 2019 and 2030 Figure 12.7: Zolgensma Drug Delivery Devices (by Volume), 2019 and 2030 Figure 12.8: Zolgensma Drug Delivery Devices (by Value), 2019 and 2030 Figure 12.9: Yescarta Drug Delivery Devices (by Volume), 2019 and 2030 Figure 12.10: Yescarta Drug Delivery Devices (by Value), 2019 and 2030 Figure 12.11: Strimvelis Drug Delivery Devices (by Volume), 2019 and 2030 Figure 12.12: Strimvelis Drug Delivery Devices (by Value), 2019 and 2030 Figure 13.1: Global Cell and Gene Therapy Drug Delivery Devices Market (by Region) Figure 13.2: Global Cell and Gene Therapy Drug Delivery Devices Market (by Region), 2019 and 2030 Figure 13.3: North America Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.4: North America: Market Dynamics Figure 13.5: U.S. Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.6: Projections of the Older Adult Population in the U.S.: 2016 to 2060 (Thousand) Figure 13.7: Canada Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.8: Europe Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.9: Europe-Market Dynamics Figure 13.10: Germany Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.11: France Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.12: U.K. Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.13: Italy Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.14: Spain Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.15: Netherlands Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.16: Russia Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.17: Rest-of-Europe Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.18: Europe Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.19: Asia-Pacific: Market Dynamics Figure 13.20: Japan Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.21: China Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.22: Australia Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.23: South Korea Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.24: Singapore Cell and Gene Therapy Drug Delivery Devices Market, 2020-2030 Figure 13.25: Rest-of-Asia-Pacific Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.26: Latin America Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.27: Latin America: Market Dynamics Figure 13.28: Brazil Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.29: Mexico Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.30: Rest-of-Latin America Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030 Figure 13.31: Rest-of-World Cell and Gene Therapy Drug Delivery Devices Market, 2020-2030 Figure 14.1: Share of Key Developments and Strategies, January 2016-January 2021 Figure 14.2: Regulatory and Legal Developments Share (by Company), January 2016-January 2021 Figure 14.3: Synergistic Activities (by Company), January 2016-January 2021 Figure 14.4: Company Share (by Synergistic Activity), January 2016-January 2021 Figure 14.5: M&A Activities Share (by Company), January 2016-January 2021 Figure 14.6: Funding Activities (by Company), January 2016-January 2021 Figure 14.7: Market Share Analysis for the Global Cell Therapy and Gene Drug Delivery Devices Market, 2019 Figure 15.1: Total Number of Companies Profiled Figure 15.2: Amgen Inc.: Overall Product Portfolio Figure 15.3: Amgen Inc.: Pipeline Product Portfolio Figure 15.4: Amgen, Inc.: Overall Financials, 2017-2019 Figure 15.5: Amgen, Inc.: Sales (by Product), 2017-2019 Figure 15.6: Amgen, Inc.: Revenue (by Region), 2017-2019 Figure 15.7: Amgen, Inc.: R&D Expenditure, 2017-2019 Figure 15.8: Amgen Inc.: SWOT Analysis Figure 15.9: Product Portfolio: Bausch & Lomb Incorporated., Figure 15.10: Bausch & Lomb Incorporated.: Overall Financials, 2017-2019 Figure 15.11: Bausch & Lomb Incorporated.: R&D Expenditure, 2017-2019 Figure 15.12: Bausch & Lomb Incorporated.: SWOT Analysis Figure 15.13: Becton, Dickinson and Company: Overall Financials, 2017-2019 Figure 15.14: Becton, Dickinson and Company: Revenue (by Segment), 2017-2019 Figure 15.15: Becton, Dickinson and Company: Revenue Split for BD Life Sciences, 2017-2019 Figure 15.16: Becton, Dickinson and Company: Revenue (by Region), 2017-2019 Figure 15.17: Becton, Dickinson and Company: R&D Expenditure, 2017-2019 Figure 15.19: Pipeline Product Portfolio: Bluebird Bio, Inc. Figure 15.20: Bluebird Bio Inc: Overall Financials, 2017-2019 Figure 15.21: Bluebird Bio Inc: R&D Expenditure, 2017-2019 Figure 15.22: bluebird bio, Inc.: SWOT Analysis Figure 15.23: Castle Creek Biosciences, Inc.: Overall Product Portfolio Figure 15.24: Castle Creek Biosciences, Inc.: Pipeline Product Portfolio Figure 15.25: Castle Creek Biosciences, Inc.: R&D Expenditure, 2017-2018 Figure 15.26: Castle Creek Biosciences, Inc.: SWOT Analysis Figure 15.27: Dendreon Pharmaceuticals LLC: Product Portfolio Figure 15.28: Dendreon Pharmaceuticals LLC.: SWOT Analysis Figure 15.29: Helixmith Co., Ltd.: Pipeline Product Portfolio Figure 15.30: ViroMed Co: Overall Financials, 2016-2018 Figure 15.31: Helixmith Co., Ltd.: SWOT Analysis Figure 15.32: Human Stem Cell Institute: Overall Product Portfolio Figure 15.33: Human Stem Cell Institute: SWOT Analysis Figure 15.34: Kite Pharma, Inc: Overall Product Portfolio Figure 15.35: Kite Pharma, Inc.: Pipeline Product Portfolio Figure 15.36: Kite Pharma, Inc: Overall Financials, 2017-2019 Figure 15.37: Kite Pharma, Inc: Revenue (by Segment), 2017-2019 Figure 15.38: Kite Pharma, Inc: Revenue (by Region), 2017-2019 Figure 15.39: Kite Pharma, Inc: R&D Expenditure, 2017-2019 Figure 15.40: Kite Pharma, Inc.: SWOT Analysis Figure 15.41: Kolon TissueGene, Inc.: Pipeline Product Portfolio Figure 15.42: Kolon TissueGene, Inc.: SWOT Analysis Figure 15.43: Novartis AG: Overall Product Portfolio Figure 15.44: Novartis AG: Pipeline Product Portfolio Figure 15.45: Novartis AG: Overall Financials, 2017-2019 Figure 15.46: Novartis AG Net Revenue (by Business Segment), 2017-2019 Figure 15.47: Novartis AG: Net Revenue (by Region), 2017-2019 Figure 15.48: Novartis AG: R&D Expense, 2017-2019 Figure 15.49: Novartis AG: SWOT Analysis Figure 15.50: Orchard Therapeutics plc.: Pipeline Product Portfolio Figure 15.51: Orchard Therapeutics plc.: Overall Financials, 2016-2018 Figure 15.52: Orchard Therapeutics plc: SWOT Analysis Figure 15.53: Pfizer, Inc.: Pipeline Product Portfolio Figure 15.54: Pfizer Inc.: Overall Financials, 2017-2019 Figure 15.55: Pfizer Inc.: Revenue (by Segment), 2017-2019 Figure 15.56: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019 Figure 15.57: Pfizer Inc.: Revenue (by Region), 2017-2019 Figure 15.58: Pfizer Inc: R&D Expenditure, 2017-2019 Figure 15.59: Pfizer, Inc.: SWOT Analysis Figure 15.60: Renova Therapeutics: Pipeline Product Portfolio Figure 15.61: Renova Therapeutics: SWOT Analysis Figure 15.62: Spark Therapeutics, Inc.: Overall Product Portfolio Figure 15.63: Spark Therapeutics, Inc.: Pipeline Product Portfolio Figure 15.64: Spark Therapeutics, Inc.: Overall Financials, 2015-2017 Figure 15.65: Spark Therapeutics, Inc.: R&D Expenditure, 2015-2017 Figure 15.66: Spark Therapeutics, Inc.: SWOT Analysis Figure 15.67: uniQure N.V.: Pipeline Product Portfolio Figure 15.68: uniQure N.V.: SWOT Analysis Figure 15.69: Vericel Corporation: Overall Product Portfolio Figure 15.70: Vericel Corporation: Pipeline Product Portfolio Figure 15.71: Vericel Corporation: Overall Financials, 2016-2018 Figure 15.72: Vericel Corporation: Revenue (by Product), 2016-2018 Figure 15.73: Vericel Corporation: R&D Expenditure (2016-2018) Figure 15.74: Vericel Corporation: SWOT Analysis